**Supplementary table 1:** **chemotherapy regimens received in patients with hepatocholangiocarcinoma in first and second lines**

|  |  |  |
| --- | --- | --- |
|  | Types of treatments | Number of patients |
| First line treatments (83 patients) |
| Tyrosine kinase inhibitor (n=25) | Sorafenib | 23 |
| Sorafenib-everolimus | 1 |
| Sunitinib | 1 |
| Platinum based chemotherapy (n=54) | LV5FU2-cisplatine | 1 |
| Gemcitabine-oxaliplatine-bevacizumab | 5 |
| Gemcitabine-oxaliplatine | 36 |
| Gemcitabine-cisplatine | 11 |
| LV5FU2-oxaliplatine | 1 |
| Others (n=4) | FGFR4 inhibitor | 1 |
| Gemcitabine-oxalipatine-sorafenib | 1 |
| Gemcitabine-aurora kinase inhibitor | 1 |
|  | Gemcitabine | 1 |
| Second line treatments (44 patients) |
| Tyrosine kinase inhibitor (n=17) | Lenvantinib | 1 |
| Sunitinib | 2 |
| Cabozantinib | 1 |
| Sorafenib | 8 |
| Regorafenib | 5 |
| Platinum based chemotherapy (n=12) | Gemcitabine-oxaliplatine | 8 |
| Gemcitabine-cisplatine | 2 |
| LV5FU2-cisplatine | 1 |
| LV5FU2-oxaliplatine | 1 |
| Others (n=15) | LV5FU2-irinotecan | 6 |
| Gemcitabine | 5 |
| Capecitabine | 2 |
| Atezolizumab-bevacizumab | 1 |
| Gemcitabine-bevacizumab | 1 |

LV5FU2 : fluorouracil and leucovorin